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Editorial on the Research Topic
Metabolic Control of Brain Homeostasis
Fundamental metabolic processes determine homeostasis of neuronal and glial networks at the
molecular, cellular, and systems levels. Metabolic resilience promotes brain health and has the
potential to prevent or reverse brain disease. A renewed and increasing interest in the relationship
between metabolism and homeostasis is evident across multiple disciplines and has the potential
to spawn new insights and therapeutic targets. The striking lack of effective treatments in disorders
such as brain cancer, Alzheimer’s disease, epilepsy, and autism spectrum disorder (ASD) highlights
the limitations of conventional, discipline-specific pharmacological approaches.
For this Research Topic authors were encouraged to submit basic research on homeostasis
and excitability as well as metabolic mechanisms associated with neurological diseases and novel
treatment approaches based onmetabolic and homeostatic interventions. This special issue features
several papers examining molecular mechanisms involved in neural network homeostasis and
higher brain function. From an evolutionary perspective, “early” metabolites such as adenosine
(a structural component of ATP and RNA) and glycine (the simplest amino acid) assumed multiple
functions as structural building blocks of cellular systems, as biochemical metabolites involved
in energy and carbon homeostasis, as epigenetic modulators, and finally (i.e., an evolutionarily
“late” function) as receptor ligands and signaling molecules. Not surprisingly, dysregulation of
those key metabolites is implicated in virtually every neurological condition, whereas therapeutic
reconstruction of biochemical homeostasis has potential for disease prevention and cure (Boison).
A molecular link to basic biochemical mechanisms is further provided in an original research
article that ascribes a specific role of the methionine cycle-associated enzyme enolase phosphatase
1 in apoptotic response mechanisms triggered by oxidative stress (Zhang et al.). The link between
metabolic homeostasis and neuronal activity is evident in the relationship between ion homeostasis
and energy demand of fast neuronal network oscillations associated with higher brain functions—
including sensory perception, attentional selection, and memory formation and requiring timed
synaptic excitation and inhibition with glutamate and GABA, respectively (Kann et al.). Fast
neuronal network oscillations are characterized by high oxygen consumption and significant
changes in the cellular redox state, indicating rapid adaptations in glycolysis and oxidative
phosphorylation. A second review article highlights the complex role of glycogen and its role in
brain energy and particularly synaptic plasticity (Waitt et al.). Exquisite sensitivity to metabolic
stress is essential for adaptation and plasticity and confers vulnerability of higher brain functions
to injury and disease.
Advances in sequencing technologies led to the discovery of amino acid-recoding RNA editing
in many gene transcripts. In this context, recent advances in A-to-I and C-to-U RNA editing are
reviewed. This mechanism points to the systemic relevance of the neurotransmitter receptor for
glycine (GlyR) and possible clues to disease mechanisms. C-to-U RNA editing of GlyR-coding
transcripts is increased in the hippocampus of patients with intractable temporal lobe epilepsy
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and can provoke completely different symptoms depending on
the neuron type that is affected (Winkelmann et al., 2014;
Çalis¸kan et al., 2016). These recent discoveries provide further
evidence for the concept of excitatory/inhibitory “imbalance”
in current psychiatric neuroscience (Eichler and Meier, 2008),
but we ultimately need to identify susceptible neuron types
and, in particular, differentiate among “inhibitory” GABAergic
neuron types (Lovett-Barron et al., 2014; Çalis¸kan et al., 2016;
Meier et al.). An excitatory/inhibitory “imbalance” and excess
excitability can have many causes: Westmark et al. delineate
the homeostatic role of amyloid-β protein precursor (APP)
and its metabolites in fragile X syndrome in humans and
in the Fmr1KO mouse model. APP seems to serve as a
rheostat where too much or too little causes hyperexcitability—
suggesting that normalizing APP levels can address aspects of this
pathophysiology.
Regarding translational and clinical research, a study of
the healthy human brain indicates the existence of specific
metabolomic profiles in different brain regions (Cabré et al.).
An analysis of post-traumatic brain injury cerebrospinal fluid
finds that mortality at 6 months can be predicted by levels of
cortisol and BDNF, particularly in younger people, and suggests
a regulatory role for cortisol (Munoz et al.). Several articles
look at changes mobilized by a metabolic therapy used to treat
epileptic seizures for nearly 100 years: the ketogenic diet (Masino,
2017). These studies include strategies to mimic the diet in
vitro and in transitional in vitro/in vivo models (Kawamura
et al.). In an original research paper, anxiolytic behavioral
effects of ketone-based metabolism—mobilized by administering
a ketone ester to induce nutritional ketosis—are reported in
two rat strains (Ari et al.). A second original paper compared
ketosis induced by exogenous ketones vs. a ketogenic diet and
found similar biochemical changes but more robust behavioral
effects of the diet (Brownlow et al.). Laboratory and clinical
evidence is reviewed regarding the prevalence of dysfunctional
mitochondria and altered metabolism in ASD alongside current
limited but positive data on the role of ketogenic diets and
metabolic therapy in reducing ASD symptoms and common
comorbidities—potentially via adenosine or other mechanisms
(Cheng et al.). An original research article demonstrates that
enhancing adenosine in brain through pharmacological blockade
of the enzyme adenosine kinase prevents radiation-induced
cognitive impairment in rats (Acharya et al.).
Finally, the role of metabolic factors and the promise of
metabolic therapy in brain cancer and Alzheimer’s disease
are implicated directly in several articles: an original research
article reveals a critical role of the proneural basic helix-
loop-helix transcription factor human achaete-scute homolog
1 (hASH1) in neuroblastoma. This study shows that hASH1
suppresses neuronal differentiation by inhibiting transcription
at the retinoic acid receptor element, highlighting hASH1 as a
key determinant of neuroblastoma resistance to differentiation
therapy (Kasim et al.). Metabolic therapy with a ketogenic
diet is highlighted as a multifaceted therapy for glioma,
particularly glioblastoma, and clinical and basic research is
reviewed indicating that a metabolic approach may both limit
tumor growth and augment the efficacy of chemotherapy and
radiation (Woolf et al.). Finally, hypometabolism is a hallmark
of Alzheimer’s disease, and regional glucose hypometabolism is
also found in patients at risk for Alzheimer’s disease and may be
a presymptomatic marker. However, hypometabolism is reversed
by administering ketones as an alternative fuel—suggesting that
a selective problem with glucose metabolism may underlie the
pathophysiology of early onset Alzheimer’s disease, and that a
metabolic therapy may prevent or delay the disorder (Cunnane
et al.).
Taken together, this research topic provides a cross-
cutting perspective of the relationship between metabolism and
homeostasis and showcases novel metabolic therapies to restore
molecular and biochemical networks. The direct and potentially
imminent clinical implications of several of these articles will be
exciting to follow as the field moves forward. While a range of
topics andmechanisms is featured herein, there is room formuch
more.
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